Regentis Biomaterials Ltd to Become Publicly Listed on Nasdaq via Business Combination with OceanTech Acquisitions I Corp.
Regentis Biomaterials Ltd ("Regentis") is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore the health and enhance quality of life of patients.
Regentis' lead product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into a resorbable implant in the knee for the treatment of painful injuries to articular knee cartilage. There is currently no approved off-the-shelf product marketed in the United States for cartilage repair. GelrinC is already approved as a device with a CE mark in Europe, and Regentis is currently conducting a pivotal trial, under the FDA sanctioned protocol, in the United States and Europe.
The transac
